AB

Bibliografia publikacji pracowników
Państwowej Szkoły Wyższej w Białej Podlaskiej

Baza tworzona przez Bibliotekę Akademii Bialskiej im. Jana Pawła II.



Zapytanie: DRUG REPURPOSING
Liczba odnalezionych rekordów: 1



Przejście do opcji zmiany formatu | Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie
1/1
Nr opisu: 0000044217
Autorzy: Marzena Lazarczyk, Kamil Duda, Michel Edward Mickael, Onurhan AK, Justyna Paszkiewicz, Agnieszka Kowalczyk, Jarosław Olav Horbańczuk, Mariusz Sacharczuk.
Tytuł pracy: Adera 2.0. A Drug Repurposing Workflow for Neuroimmunological Investigations Using Neural Networks
Tytuł czasopisma:
Szczegóły: 2022, Vol. 27, issue 19, article number 6453
p-ISSN: 1420-3049

Charakterystyka formalna: artykuł w czasopiśmie zagranicznym
Charakterystyka merytoryczna: artykuł oryginalny naukowy
Charakterystyka wg MNiSW: artykuł w czasopiśmie z IF (wykaz MEiN)
Język publikacji: ENG
Wskaźnik Impact Factor ISI: 4.600
Punktacja ministerstwa: 140.000
Słowa kluczowe ang.: deep neural network ; drug repurposing ; neuro-immunology
https://www.mdpi.com/1420-3049/27/19/6453
DOI: 10.3390/molecules27196453
Streszczenie: Drug repurposing in the context of neuroimmunological (NI) investigations is still in its primary stages. Drug repurposing is an important method that bypasses lengthy drug discovery procedures and focuses on discovering new usages for known medications. Neuroimmunological diseases, such as Alzheimer's, Parkinson's, multiple sclerosis, and depression, include various pathologies that result from the interaction between the central nervous system and the immune system. However, the repurposing of NI medications is hindered by the vast amount of information that needs mining. We previously presented Adera1.0, which was capable of text mining PubMed for answering query-based questions. However, Adera1.0 was not able to automatically identify chemical compounds within relevant sentences. To challenge the need for repurposing known medications for neuroimmunological diseases, we built a deep neural network named Adera2.0 to perform drug repurposing. The workflow uses three deep learning networks. The first network is an encoder and its main task is to embed text into matrices. The second network uses a mean squared error (MSE) loss function to predict answers in the form of embedded matrices. The third network, which constitutes the main novelty in our updated workflow, also uses a MSE loss function. Its main usage is to extract compound names from relevant sentences resulting from the previous network. To optimize the network function, we compared eight different designs. We found that a deep neural network consisting of an RNN neural network and a leaky ReLU could achieve 0.0001 loss and 67% sensitivity. Additionally, we validated Adera2.0's ability to predict NI drug usage against the DRUG Repurposing Hub database. These results establish the ability of Adera2.0 to repurpose drug candidates that can shorten the development of the drug cycle. The workflow could be download online.

  Wyświetl ponownie stosując format:
Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka AB